Condition: Alzheimer s Disease · Alzheimer Blood Biomarkers · Insulin Sensitivity · Sponsor: Pennington Biomedical Research Center
The goal of this clinical trial is to determine if a weekly delivery of insulin at short intervals lasting up to 2 hours can improve insulin sensitivity and cognition in adults with Alzheimer's Disease. It will also provide information about the safety and feasibility of this intervention. The main questions it aims to answer are: Does the intervention improve insulin sensitivity (how the body uses glucose)? Does the intervention improve cognition, measured by the Montreal Cognitive Assessment (MoCA) and the Revised Memory and Behavior Problems Checklist (RMBPC)? What changes occur in brain glucose uptake (FDG-PET)? Participants will: Receive the intervention once a week for 6 months, with each session lasting up to 2 hours Complete cognitive assessments. Adverse events will be assessed throughout the study.
This description comes directly from the study's public registry record.
Tim Gilbert, M.D. · 2257632584 · Tim.Gilbert@pbrc.edu
Candida Rebello, Ph.D. · 2257633159 · Candida.Rebello@pbrc.edu
Always discuss trial participation with your own doctor first.
| Pennington Biomedical Research Center | Baton Rouge, Louisiana, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07265323